In this study, we found that treatment with anagliptin effectively prevented inflammation, fibrosis, and carcinogenesis in the liver of MC4R-KO mice fed WD, while only marginally affecting body weight, systemic glucose and lipid metabolism, and hepatic steatosis. This evidence concerns the gene MC4R and Wilson disease.